Summary - EVAX - NASDAQ - Weiss Ratings

E

Evaxion Biotech A/S EVAX

$1.69 $0.106.29% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$1.20 - $21.65

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Evaxion to present at World Vaccine Congress

4/10/2025 - Globe Newswire

Evaxion Biotech's Optimistic Earnings Call Highlights

4/3/2025 - TipRanks Financial Blog

Q4 2024 Evaxion Biotech A/S Earnings Call Transcript

4/2/2025 - GuruFocus

Evaxion Biotech Reports 2024 Financial Results and Strategic Progress

4/2/2025 - TipRanks Financial Blog

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

4/1/2025 - Seeking Alpha: Transcripts

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

4/1/2025 - SeekingAlpha

Evaxion Biotech A/S 2024 Q4 - Results - Earnings Call Presentation

4/1/2025 - SeekingAlpha

Evaxion announces business update and full year 2024 financial results

4/1/2025 - Globe Newswire

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

3/27/2025 - Globe Newswire

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

3/25/2025 - Globe Newswire

Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Growth in Short Interest

3/17/2025 - Ticker Report

Evaxion to present at numerous upcoming conferences

3/4/2025 - Globe Newswire

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

2/25/2025 - Globe Newswire

Evaxion Biotech A/S (NASDAQ:EVAX) Given "Buy" Rating at HC Wainwright

2/21/2025 - Ticker Report

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

2/14/2025 - Globe Newswire

Evaxion Biotech A/S (NASDAQ:EVAX) Price Target Cut to $6.00 by Analysts at Lake Street Capital

2/6/2025 - Ticker Report

Evaxion announces closing of $10.8 million public offering

1/31/2025 - Globe Newswire

Evaxion announces pricing of $10.8 million public offering

1/30/2025 - Globe Newswire

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

1/28/2025 - Globe Newswire

Head to Head Contrast: Novozymes A/S (OTCMKTS:NVZMY) versus Evaxion Biotech A/S (NASDAQ:EVAX)

1/22/2025 - Ticker Report

Evaxion Biotech A/S (NASDAQ:EVAX) & SAB Biotherapeutics (NASDAQ:SABS) Critical Survey

1/16/2025 - Ticker Report

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

1/15/2025 - Globe Newswire

Evaxion announces completion of ADS ratio change

1/14/2025 - Globe Newswire

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

1/10/2025 - Globe Newswire

Evaxion Biotech A/S (NASDAQ:EVAX) versus MiNK Therapeutics (NASDAQ:INKT) Financial Contrast

1/10/2025 - Ticker Report

Income Statement

Total Revenue (TTM)

--

EBITDA (TTM)

--

EBIT (TTM)

--

Net Income (TTM)

--

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

--

Cash from Investing (TTM)

--

Cash from Financing (TTM)

--

Net Change in Cash (TTM)

--

Filings

Filing Date

Tuesday, April 1, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Week of May 26 and 30 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

--

52-week Low

Apr 10, 2025 - $1.20

52-week High

Apr 26, 2024 - $21.65

Valuation

Market Cap

$9.96M - Nano Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

Phone Number

45 31 31 97 53

Address

Dr. Neergaards Vej
Horsholm, 2970

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center... more